Copyright
©The Author(s) 2020.
World J Cardiol. Nov 26, 2020; 12(11): 571-583
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.571
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.571
Junquera et al[2] | Fernandez-Lopez et al[6] | Jackson et al[5] | Allende et al[4] | Curran et al[3] | |
Study details | |||||
Year of publication | 2020 | 2018 | 2018 | 2014 | 2014 |
Country of origin | Multinational (Canada, Europe) | France | The United Kingdom | Canada | Italy |
Number of centers | Multicenter | Single center | Single center | Single center | Single center |
Study design | Retrospective and prospective cohort study | Retrospective and prospective cohort study | Retrospective cohort study | Retrospective cohort study | Retrospective cohort study |
Study subjects | A total of 4949 patients who underwent TAVI between 2007 and 2018 in 10 tertiary centers were included. Selection of secondary access was up to the heart team. 3906 subjects had matched outcomes | Retrospective cohort of 194 patients underwent TFSA TAVI between Sept 2015 and Apr 2016. Prospective cohort of 217 pts underwent TRSA TAVI between April 2016 and May 2017 | All consecutive TAVI cases between May 2015 and June 2017 included. Default TRSA used for all non-TF TAVIs from Jan 2016. Prior to this, secondary access was selected based on clinical grounds | Consecutive patients who underwent TAVI from 2007 to 2014 enrolled. From May 2007-Jan 2013, TFSA was chosen. From Jan 2013 onwards, TRSA was chosen in TFPA TAVI and some non-TFPA TAVI | A total of 87 consecutive patients who underwent TFPA TAVI between June 2011 and March 2012 were included in the study. The first 46 TRSA candidates and 41 TFSA candidates were considered |
Primary access | TF + non-TF | TF only | TF + non-TF | TF + non-TF | TF only |
Total No. of study subjects (APA) with matched or adjusted data if available | 3906 (TRSA = 928, TFSA = 2978) | 411 (TRSA = 217, TFSA = 194) | 199 (TRSA = 135, TFSA = 64) | 462 (TRSA = 127, TFSA = 335) | 87 (TRSA = 46, TFSA = 41) |
Total No. of study subjects (TFPA) with matched or adjusted data | NA | 411 (TRSA = 217, TFSA = 194) | 179 (TRSA = 115, TFSA = 64) | 221 (TRSA = 118, TFSA = 103) | 87 (TRSA = 46, TFSA = 41) |
Definition of bleeding and vascular events | VARC-2 criteria | VARC-2 criteria | VARC-2 criteria | VARC-2 criteria | Original VARC criteria |
Limitations of study | Nonrandomized study | (1) Non-randomized study; (2) Relatively small sample size; (3) TFSA technique was novel resulting in a learning curve | (1) Non-randomized study; (2) Relatively small sample size; (3) Unclear if there was a difference in the populations (risk adjustment not reported) | (1) Non-randomized study; (2) Relatively small sample size; (3) Low use of percutaneous closure devices (13%) for obtaining hemostasis in TFSA | (1) Non-randomized study; (2) Relatively small sample size; (3) TFSA technique was novel resulting in a learning curve |
Was risk-adjustment done? | Both unadjusted and propensity score-matched data available | Adjusted for age, Euroscore, BMI, NYHA class, type, and size of valve | Not reported | Adjusted for gender and peripheral disease | Not reported |
TAVI Procedure details | |||||
Hemostasis of PA | TFPA—Percutaneous in 76.3%, surgical cutdown in 23.7% | TFPA—ProGlide device | TFPA—2 ProGlide devices | TFPA—surgical cutdown | NA |
Hemostasis of TF secondary access | Manual compression (24%), ProGlide (39%), Angio-Seal (37%) | Angio-Seal or ProGlide | NA | Manual compression (87%), ProGlide (8%), Angio-Seal (5%) | NA |
Post-closure angiography? | No angiography was performed systematically in TFPA |
Junquera et al[2] | Fernandez-Lopez et al[6] | Jackson et al[5] | Allende et al[4] | Curran et al[3] | ||||||
TFSA (n = 2978) | TRSA (n = 928) | TFSA (n = 194) | TRSA (n = 217) | TFSA (n = 64) | TRSA (n = 135) | TFSA (n = 335) | TRSA (n = 127) | TFSA (n = 41) | TRSA (n = 46) | |
Baseline characteristics of patients | ||||||||||
Age | 81 ± 4 | 81 ± 8 | 83 ± 7 | 82 ± 6 | 82 ± 6 | 82 ± 7 | 79 ± 8 | 80 ± 9 | 80 ± 10 | 80 ± 5 |
%Male | 52.60% | 53.20% | 44.80% | 53.50% | 57.00% | 43.00% | 45.00% | 61.00% | 31.70% | 52.20% |
Baseline comorbidities | ||||||||||
Diabetes | 26.90% | 27.00% | 31.40% | 24.40% | 20.00% | 20.00% | 35.00% | 31.00% | 30.00% | 26.10% |
HTN | - | - | 56.70% | 55.30% | - | - | 88.00% | 84.00% | 92.50% | 80.40% |
CAD | 51.20% | 50.30% | - | - | 53.00% | 52.60% | 67.00% | 63.00% | - | - |
Previous CABG | 19.80% | 19.60% | 4.10% | 6.00% | 20.00% | 19.30% | 39.00% | 33.00% | 17.10% | 17.40% |
AFib | 33.50% | 34.70% | 27.80% | 33.60% | 25.00% | 25.00% | 17.00% | 20.00% | - | - |
PVD | 16.30% | 19.20% | 13.40% | 14.30% | 18.00% | 26.70% | 40.00% | 24.00% | - | - |
Prior CVA | - | - | 10.30% | 10.60% | 17.00% | 16.30% | 19.00% | 16.00% | - | - |
eGFR < 60 mL/min/1.73 m2 | 67.60% | 69.40% | - | - | - | - | 57.00% | 51.00% | - | - |
COPD/Pul disease | 21.30% | 20.90% | 11.90% | 13.40% | 25.00% | 25.90% | 29.00% | 25.00% | 20.00% | 13.00% |
STS-PROM score | 4.5 | 4.7 | 5.0 ± 3.0 | 4.8 ± 3.6 | - | - | 7.1 ± 4.5 | 7.2 ± 5.0 | 9.0 ± 7.8 | 7.2 ± 7.5 |
Valve type | ||||||||||
Balloon-expandable | 60.00% | 63.50% | NA | NA | NA | NA | 96.00% | 88.00% | NA | NA |
Self-expandable | 40.00% | 36.50% | NA | NA | NA | NA | 3.00% | 10.00% | NA | NA |
1° Access | ||||||||||
TFPA | 88.50% | 89.90% | 100% | 100% | 100% | 85.20% | 30.80% | 93.00% | 100% | 100% |
Non-TFPA | 11.50% | 10.10% | 0 | 0 | 0 | 14.80% | 69.20% | 7.00% | 0 | 0 |
Transapical | 9.10% | 3.70% | 58.20% | 6.00% | ||||||
Transaortic | 1.90% | 8.80% | 10.70% | 1.00% | ||||||
Subclavian | 1.50% | 2.20% | 0.30% | 0 | ||||||
Transcarotid | 4.06% | 0 | 0 | 0 | ||||||
Transcaval | 0.12% | 0 | 0 | 0 |
- Citation: Radhakrishnan SL, Ho KKL. Transradial vs transfemoral secondary access outcomes in transcatheter aortic valve implantation: A systematic review and meta-analysis. World J Cardiol 2020; 12(11): 571-583
- URL: https://www.wjgnet.com/1949-8462/full/v12/i11/571.htm
- DOI: https://dx.doi.org/10.4330/wjc.v12.i11.571